Elanco Animal Health reports Q1 2026 results on May 6 with the Street broadly constructive — but the stock has spent the past month drifting lower, testing how much of that optimism is already in the price.
The analyst backdrop is unusually bullish for a mid-cap pharma name. The consensus sits 27% above the current price of $22.51, and the analyst recommendation differential ranks in the 92nd percentile of the universe — meaning very few stocks have a more positively skewed rating distribution. Citigroup initiated coverage with a Buy and a $30 target in mid-April. Multiple firms raised targets after the last print in February, including JPMorgan to $28 and Leerink Partners to $30. Morgan Stanley held at Equal-Weight with a $24 target — effectively the cautious outlier in an otherwise bullish crowd. Forward EPS estimates are also tracking higher on a year-over-year basis, ranking in the 79th percentile.
The bull case centres on product-level momentum. Simparica Trio commands more than 50% market share in its category, and Credelio Quattro is expected to grow meaningfully through 2026. Key legacy brands like Advantage Family and Seresto have posted strong annual growth. Bears point elsewhere: the company carries significant debt, and refinancing in a higher-rate environment poses a real constraint on near-term earnings leverage. Despite revenue gains, EBITDA margins have faced pressure, raising questions about whether top-line growth can flow through to the bottom line. That tension — volume expansion versus margin dilution — is exactly what the Q1 print will illuminate.
Short positioning tells a quiet story. SI is running at roughly 4.6% of the free float, down 8% on the week as shorts have been covering. Borrowing costs remain negligible at 0.49%, and borrow availability is well supplied, with no signs of pressure in the lending market. Options have turned slightly more defensive than recent norms — the put/call ratio is at 0.74, about 1.4 standard deviations above its 20-day average of 0.61, suggesting modest hedging activity rather than outright fear. After the last earnings release in late February, the stock jumped 8.4% on the day. The May 6 print will test whether the current combination of bullish analyst framing and compressed short interest can hold against a stock that has given back 6% over the past month.
See the live data behind this article on ORTEX.
Open ELAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
